<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 3pt; border-top: Black 3pt solid; border-bottom: Black 3pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 25%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">October 23, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 25%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MULTICELL TECHNOLOGIES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 32%; padding-right: 0.7pt; padding-left: 0.7pt; font-weight: bold; text-decoration: underline; text-align: center">Delaware</TD>
    <TD STYLE="vertical-align: bottom; width: 2%; padding-right: 0.7pt; padding-left: 0.7pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; padding-right: 0.7pt; padding-left: 0.7pt; font-weight: bold; text-decoration: underline; text-align: center"><B><U>001-10221</U></B></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; padding-right: 0.7pt; padding-left: 0.7pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; padding-right: 0.7pt; padding-left: 0.7pt; font-weight: bold; text-decoration: underline; text-align: center">52-1412493</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.7pt; padding-left: 0.7pt; text-align: center">(State or other jurisdiction of incorporation)</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.7pt; padding-left: 0.7pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.7pt; padding-left: 0.7pt; text-align: center">(Commission&nbsp; File Number)</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.7pt; padding-left: 0.7pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.7pt; padding-left: 0.7pt; text-align: center">(IRS Employer<BR> Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>68 Cumberland Street, Suite 301</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Woonsocket, RI 02895</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices,
including zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(401) 762-0045</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 3pt; border-top: Black 3pt solid; border-bottom: Black 3pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.01 Entry into a Material Definitive Agreement. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 23, 2012 Xenogenics Corporation
(the &ldquo;Purchaser&rdquo;), a subsidiary of MultiCell Technologies, Inc. (the &ldquo;Registrant&rdquo;), entered into an Amendment
No. 2 (the &ldquo;Amendment No. 2&rdquo;) to Foreclosure Sale Agreement (the &ldquo;Agreement&rdquo;) with Venture Lending&nbsp;&amp;
Leasing IV, Inc. (&ldquo;VLL4&rdquo;), Venture Lending &amp; Leasing V, Inc. (&ldquo;VLL5&rdquo;) and Silicon Valley Bank (&ldquo;SVB&rdquo;).
VLL4, VLL5 and SVB are sometimes referred to hereinafter collectively as &ldquo;Sellers&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">The Sellers
previously entered into the Agreement with the Purchaser on September 30, 2010. An Amendment No. 1 to Foreclosure Sale Agreement
was executed on September 30, 2011 (the &ldquo;Amendment No. 1&rdquo;). </FONT>The foregoing descriptions of the Agreement and
the Amendment No. 1 are qualified in their entirety by reference to the full text of such Agreement and such Amendment No. 1, copies
of which is filed as Exhibit 10.2 to <FONT STYLE="color: black">the Registrant&rsquo;s Current Report on Form 8-K filed on October
20, 2010,</FONT> and Exhibit 10.1 to the Registrant&rsquo;s Current Report on Form 8-K filed on October 6, 2011, and are hereby
incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">Under the terms
of Amendment No. 2 to Foreclosure Agreement, the deadlines for the achievement of certain milestones under the Agreement are extended.
The deadline to restart manufacturing of the Generation 2 bio-absorbable stent device was extended to 24 months from the date of
execution of Amendment No. 1; the deadline to initiate an animal study was extended to within 30 months from the date of execution
of Amendment No. 1; the deadline to make a regulatory submission to support a human use clinical trial was extended to within 36
months from the date of execution of Amendment No. 1; the deadline to initiate a human use clinical trial was extended to within
48 months from the date of execution of Amendment No. 1; and the deadline to make a regulatory submission or equivalent for marketing
approval for use in humans was extended to within 60 months from the date of execution of Amendment No. 1. </FONT>The foregoing
description of the Amendment No. 2 is qualified in its entirety by reference to the full text of such agreement, a copy of which
is filed as Exhibit 10.1 hereto, and is hereby incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Item 9.01 </B></FONT>&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Exhibits </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>(</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">d</FONT><FONT STYLE="font-variant: small-caps">)
</FONT>Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.1</TD><TD>Amendment No. 2 To Foreclosure Sale Agreement, dated as of October 23, 2012, by and among Venture Lending &amp; Leasing IV,
Inc., Venture Lending &amp; Leasing V, Inc., Silicon Valley Bank and Xenogenics Corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.7pt; padding-left: 0.7pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; padding-left: 0.7pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0.7pt; padding-left: 0.7pt; font-weight: bold">MULTICELL TECHNOLOGIES, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.7pt; padding-left: 0.7pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; padding-left: 0.7pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0.7pt; padding-left: 0.7pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 0.7pt; padding-left: 0.7pt">&nbsp;</TD>
    <TD STYLE="width: 49%; padding-right: 0.7pt; padding-left: 0.7pt; text-align: right">By:&nbsp;&nbsp;</TD>
    <TD STYLE="width: 31%; border-bottom: windowtext 1pt solid; padding-right: 0.7pt; padding-left: 0.7pt">/s/ W. Gerald Newmin</TD>
    <TD STYLE="width: 17%; padding-right: 0.7pt; padding-left: 0.7pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.7pt; padding-left: 0.7pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0.7pt; padding-left: 0.7pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>W. Gerald Newmin</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Chief Executive Officer, Chief Financial Officer</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: <B>October 25, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v326664_8k.htm", "description": "CURRENT REPORT", "secsgml_size_bytes": 16167}]
{"company-data": {"conformed-name": "MultiCell Technologies, Inc.", "cik": "0000811779", "assigned-sic": "2834", "irs-number": "521412493", "state-of-incorporation": "DE", "fiscal-year-end": "1130"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-10221", "film-number": "121161171"}, "business-address": {"street1": "68 CUMBERLAND STREET, SUITE 301", "city": "WOONSOCKET", "state": "RI", "zip": "02865", "phone": "(401)762-0045"}, "mail-address": {"street1": "68 CUMBERLAND STREET, SUITE 301", "city": "WOONSOCKET", "state": "RI", "zip": "02865"}, "former-company": [{"former-conformed-name": "Multicell Technologies Inc.", "date-changed": "20040615"}, {"former-conformed-name": "EXTEN INDUSTRIES INC", "date-changed": "19920703"}, {"former-conformed-name": "EXTEN VENTURES INC", "date-changed": "19910923"}]}
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
October 23, 2012
MULTICELL TECHNOLOGIES, INC.
(Exact name of registrant as specified in
its charter)
Delaware
001-10221
52-1412493
(State or other jurisdiction of incorporation)
(Commission  File Number)
(IRS Employer
Identification No.)
68 Cumberland Street, Suite 301
Woonsocket, RI 02895
(Address of principal executive offices,
including zip code)
(401) 762-0045
(Registrant's telephone number, including
area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
On October 23, 2012 Xenogenics Corporation
(the "Purchaser"), a subsidiary of MultiCell Technologies, Inc. (the "Registrant"), entered into an Amendment
No. 2 (the "Amendment No. 2") to Foreclosure Sale Agreement (the "Agreement") with Venture Lending &
Leasing IV, Inc. ("VLL4"), Venture Lending & Leasing V, Inc. ("VLL5") and Silicon Valley Bank ("SVB").
VLL4, VLL5 and SVB are sometimes referred to hereinafter collectively as "Sellers".
The Sellers
previously entered into the Agreement with the Purchaser on September 30, 2010. An Amendment No. 1 to Foreclosure Sale Agreement
was executed on September 30, 2011 (the "Amendment No. 1").
The foregoing descriptions of the Agreement and
the Amendment No. 1 are qualified in their entirety by reference to the full text of such Agreement and such Amendment No. 1, copies
of which is filed as Exhibit 10.2 to
the Registrant's Current Report on Form 8-K filed on October
20, 2010,
and Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on October 6, 2011, and are hereby
incorporated by reference herein.
Under the terms
of Amendment No. 2 to Foreclosure Agreement, the deadlines for the achievement of certain milestones under the Agreement are extended.
The deadline to restart manufacturing of the Generation 2 bio-absorbable stent device was extended to 24 months from the date of
execution of Amendment No. 1; the deadline to initiate an animal study was extended to within 30 months from the date of execution
of Amendment No. 1; the deadline to make a regulatory submission to support a human use clinical trial was extended to within 36
months from the date of execution of Amendment No. 1; the deadline to initiate a human use clinical trial was extended to within
48 months from the date of execution of Amendment No. 1; and the deadline to make a regulatory submission or equivalent for marketing
approval for use in humans was extended to within 60 months from the date of execution of Amendment No. 1.
The foregoing
description of the Amendment No. 2 is qualified in its entirety by reference to the full text of such agreement, a copy of which
is filed as Exhibit 10.1 hereto, and is hereby incorporated by reference herein.
Item 9.01
Exhibits
(
d
)
Exhibits
10.1
Amendment No. 2 To Foreclosure Sale Agreement, dated as of October 23, 2012, by and among Venture Lending & Leasing IV,
Inc., Venture Lending & Leasing V, Inc., Silicon Valley Bank and Xenogenics Corporation.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MULTICELL TECHNOLOGIES, INC.
By:
/s/ W. Gerald Newmin
W. Gerald Newmin
Chief Executive Officer, Chief Financial Officer
Date:
October 25, 2012